ABK Biomedical Inc.

ABK Biomedical Inc.

Improving treatment options for patients with hypervascular tumors

Founded 2012 Canada

Canada 42 employees Series C Total: $69.44M Biotechnology, Health Care +1

ABK Biomedical Inc., established in 2012, is at the forefront of developing innovative medical device therapies aimed at enhancing treatment outcomes for patients suffering from benign and malignant hypervascular tumors. The company focuses on the burgeoning industries of Biotechnology, Health Care, and Medical Devices.

Headquartered in Canada, ABK Biomedical Inc. boasts a multidisciplinary team with expertise across various fields, including engineering, material science, oncology, regulatory affairs, and business development. This diverse talent pool positions the company to leverage cutting-edge technology for personalized healthcare solutions in oncology.

In its most recent financial milestone, ABK Biomedical Inc. secured a substantial $30.00M in a Series C investment round on 06 December 2022, with participation from prominent investors such as Eight Roads Ventures, F-Prime Capital, and Santé Ventures. This investment underscores confidence in the company’s potential to drive significant advancements in medical therapies.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$30.00M	3	Eight Roads Ventures, F-Prime Capital +1	06 Dec 2022
Series B	$30.00M	2	F-Prime Capital, Varian	08 Apr 2019
Series A	$9.44M	1	Innovacorp	22 Jun 2016
Angel Round	Undisclosed	2	Wilmington Investor Network, First Angel Network	01 Jan 2014
Seed Round	Undisclosed	1	Innovacorp	15 Sep 2012

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$30.00M

Eight Roads Ventures, F-Prime Capital +1

06 Dec 2022

Series B

$30.00M

F-Prime Capital, Varian

08 Apr 2019

Series A

$9.44M

Innovacorp

22 Jun 2016

Angel Round

Undisclosed

Wilmington Investor Network, First Angel Network

01 Jan 2014

Seed Round

Undisclosed

Innovacorp

15 Sep 2012

FAQ About ABK Biomedical Inc.

Improving treatment options for patients with hypervascular tumors

ABK Biomedical Inc. was founded in 2012.

ABK Biomedical Inc. is headquartered in Canada.

ABK Biomedical Inc. operates in Biotechnology, Health Care and Medical Devices. Its work centres on Hypervascular Tumors, Medical Device Development, Interventional Radiology and Tumor Embolization. Its customers include Oncologists, Interventional Radiologists and Medical Researchers.

ABK Biomedical Inc. has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.

ABK Biomedical Inc. has approximately 42 employees.

ABK Biomedical Inc. has completed 5 funding rounds, raising a total of $69.44M. The latest funding stage is Series C.

ABK Biomedical Inc. offers: Research and Development of Medical Devices, Commercialization of Imageable Embolic Therapies, Clinical Trials for New Cancer Treatments.

Top alternatives and competitors to ABK Biomedical Inc. include Yaqrit, NBE-Therapeutics AG, ASC Oncology GmbH, Prescient Therapeutics, dianosic. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ABK Biomedical Inc. and Yaqrit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About ABK Biomedical Inc.

Services & Products

Target Customers

Funding Rounds & Investors (5)

ABK Biomedical Inc. Alternatives & Competitors

FAQ About ABK Biomedical Inc.